Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer

Aim To investigate differences of platelet indices in breast cancer patients after tamoxifen (tmx) and anastrazole adjuvant treatment. Methods In this retrospective study, 46 postmenopausal women (20 with tmx and 26 with anastrazole) with breast cancer who received adjuvant hormone therapy were enrolled. The biochemical and complete blood count (CBC) parameters were documented before hormone treatment start and after 1 year. Results The lymphocyte count was higher after tmx use, but not anastrazole. Total white blood cells were increased both after 1-year tmx and anastrazole using. Mean platelet volume (MPV) increased after tmx use (8.2 ± 0.94–8.97 ± 0.97; P: 0.041), while it was not different after anastrazole use (7.96 ± 1.08–7.89 ± 0.99; P: 0.585). Other platelet parameters did not alter with tmx or anastrazole treatment. Conclusion We found increased MPV after tmx treatment, but did not after anastrazole treatment. The advanced studies which explore biological significance of high MPV in breast cancer patients used endocrine therapy, should be established.